Automated calculation and reporting of vancomycin area under the concentration-time curve: a simplified single-trough concentration-based equation approach

被引:0
作者
Kim, Hyun-Ki [1 ]
Jeong, Tae-Dong [2 ]
Ji, Misuk [3 ]
Kim, Sollip [4 ,5 ]
Lee, Woochang [4 ,5 ]
Chun, Sail [4 ,5 ]
机构
[1] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Lab Med, Ulsan, South Korea
[2] Ewha Womans Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[3] Vet Hlth Serv VHS Med Ctr, Dept Lab Med, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Dept Lab Med, Seoul, South Korea
[5] Asan Med Ctr, Seoul, South Korea
关键词
vancomycin; therapeutic drug monitoring; area under the concentration-time curve; volume of distribution; STAPHYLOCOCCUS-AUREUS INFECTIONS; DRUG; PERFORMANCE;
D O I
10.1128/aac.00699-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vancomycin, a crucial antibiotic for Gram-positive bacterial infections, requires therapeutic drug monitoring (TDM). Contemporary guidelines advocate for AUC-based monitoring; however, using Bayesian programs for AUC estimation poses challenges. We aimed to develop and evaluate a simplified AUC estimation equation using a steady-state trough concentration (Ctrough) value. Utilizing 1,034 TDM records from 580 general hospitalized patients at a university-affiliated hospital in Ulsan, we created an equation named SSTA that calculates the AUC by applying Ctrough, body weight, and single dose as input variables. External validation included 326 records from 163 patients at a university-affiliated hospital in Seoul (EWUSH) and literature data from 20 patients at a university-affiliated hospital in Bangkok (MUSI). It was compared with other AUC estimation models based on the Ctrough, including a linear regression model (LR), a sophisticated model based on the first-order equation (VancoPK), and a Bayesian model (BSCt). Evaluation metrics, such as median absolute percentage error (MdAPE) and the percentage of observations within +/- 20% error (P20), were calculated. External validation using the EWUSH data set showed that SSTA, LR, VancoPK, and BSCt had MdAPE values of 6.4, 10.1, 6.6, and 7.5% and P20 values of 87.1, 82.5, 87.7, and 83.4%, respectively. External validation using the MUSI data set showed that SSTA, LR, and VancoPK had MdAPEs of 5.2, 9.4, and 7.2%, and P20 of 95, 90, and 95%, respectively. Owing to its decent AUC prediction performance, simplicity, and convenience for automated calculation and reporting, SSTA could be used as an adjunctive tool for the AUC-based TDM.
引用
收藏
页数:14
相关论文
共 35 条
  • [1] Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model-informed precision dosing trial simulations
    Aljutayli, Abdullah
    Thirion, Daniel J. G.
    Bonnefois, Guillaume
    Nekka, Fahima
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (04): : 942 - 953
  • [2] Vancomycin therapeutics and monitoring: a contemporary approach
    Avent, M. L.
    Vaska, V. L.
    Rogers, B. A.
    Cheng, A. C.
    van Hal, S. J.
    Holmes, N. E.
    Howden, B. P.
    Paterson, D. L.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (02) : 110 - 119
  • [3] Accuracy of 4 Free Online Dosing Calculators in Predicting the Vancomycin Area Under the Concentration-Time Curve Calculated Using a 2-Point Pharmacokinetic Approach
    Belz, Sarah N.
    Seabury, Robert W.
    Steele, Jeffrey M.
    Darko, William
    Miller, Christopher D.
    Probst, Luke A.
    Kufel, Wesley D.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (04) : 432 - 440
  • [4] Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets
    Bradley, Nicole
    Ng, Kimberly
    [J]. PHARMACY, 2023, 11 (03)
  • [5] Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit
    Chen, Maggie
    Lee, Colin
    Gnyra, Michelle
    Wong, Michelle
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2022, 9
  • [6] Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients
    De Waele, Jan J.
    Lipman, J.
    Akova, M.
    Bassetti, M.
    Dimopoulos, G.
    Kaukonen, M.
    Koulenti, D.
    Martin, C.
    Montravers, P.
    Rello, J.
    Rhodes, A.
    Udy, A. A.
    Starr, T.
    Wallis, S. C.
    Roberts, J. A.
    [J]. INTENSIVE CARE MEDICINE, 2014, 40 (09) : 1340 - 1351
  • [7] The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan, Philip G.
    Begg, Evan J.
    Gardiner, Sharon J.
    Kirkpatrick, Carl M. J.
    Chambers, Steve T.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (04) : 401 - 407
  • [8] Accuracy of vancomycin AUC values estimated with trough-only data in a veteran population
    Fewel, Nathan
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (06) : 390 - 394
  • [9] Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data
    Fewel, Nathan
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (05) : 1426 - 1432
  • [10] Vancomycin AUC values estimated with trough-only data: Accuracy in an adult academic medical center population
    Hannan, Kellie N. Arensman
    Rivera, Christina G.
    Fewel, Nathan
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (07) : 452 - 456